Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic agent for systemic bone disease and use thereof

A technology of bone system diseases and pharmacy, applied in bone diseases, applications, drug combinations, etc., can solve problems such as short half-life

Inactive Publication Date: 2015-05-13
NAGOYA UNIVERSITY
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The half-life of CNP is extremely short, and continuous intravenous injection is required in vivo experiments (non-patent document 6)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for systemic bone disease and use thereof
  • Therapeutic agent for systemic bone disease and use thereof
  • Therapeutic agent for systemic bone disease and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0051] In recent years, the strategy of exploring new functions of existing drugs and expanding their applications, that is, drug repositioning (drug repositioning) has attracted attention (References 20 and 21). One of the advantages of this strategy is that the optimal dosage, side effects, etc. of the identified drug have been clarified, so it can be immediately applied clinically. In the following, 1186 FDA-approved drugs were screened for the purpose of identifying agents effective in the treatment of achondroplasia (hypoplasia) and other skeletal dysplasia involving FGFR3.

[0052] 1. Materials and Methods

[0053] (1) Screening of 1186 FDA-approved drugs using rat chondrosarcoma (RCS) cells

[0054] RCS cells provided by Dr. Pavel Krejci (Medical Genetics Institute, Cedars-Sinai Medical Center, LA) were cultured in Dulbecco's modified Eagle medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Thermo Scientific) ( Reference 14). For the RSC prolife...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention addresses the problem of providing a novel therapeutic strategy which has excellent therapeutic effects on systemic bone diseases caused by over-activation of FGFR3, in particular, achondroplasia and hypochondroplasia. A therapeutic agent for systemic bone disease is provided which comprises, as an active ingredient, meclizine or a pharmaceutically acceptable salt thereof.

Description

technical field [0001] The invention relates to a medicine for treating bone system diseases and its application. The medicine for treating bone system diseases of the present invention can be used for achondroplasia, hypochondroplasia, lethal osteoplasia, Cruzon's disease, dysplasia of extremities, severe achondroplasia with growth retardation, and acanthosis nigricans Syndrome (SADDAN) etc. treatment. This application claims priority based on Japanese Patent Application No. 2013-47426 for which it applied on March 10, 2013, The whole content of this patent application is taken in in this application by reference. Background technique [0002] Achondroplasia, hypochondroplasia, is caused by persistently activating mutations in fibroblast growth factor receptor 3 (FGFR3), a negative regulator of bone extension. In addition, low stature including idiopathic short stature has also been shown to be associated with FGFR3. In achondroplasia, not only low stature occurs due to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/495A23L1/30A61P19/00A61P43/00
CPCA61K31/495A23L33/10A61P19/00A61P19/08A61P43/00A23V2002/00
Inventor 大野钦司石黑直树鬼头浩史松下雅树
Owner NAGOYA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com